Spotlight On Obesity Week: Non-incretin Alternatives Turn Up the Heat

ObesityWeek 2025; non-incretin therapies; naltrexone-bupropion; CONTRAVE; weight management; craving control; behavioral adherence; pharmaceutical innovation; cardiometabolic health

Altanine Strengthens Scientific Advisory Board with Appointment of Dr. Bruce D. Forrest

Altanine; Scientific Advisory Board; Bruce D. Forrest; drug delivery; clinical strategy; regulatory expertise; biopharmaceutical development; vaccine development; pharmaceutical innovation

PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics

PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation